Last reviewed · How we verify

NCT05988099

Comparison of the Effects of Standardized Chokeberry Extracts With Various Formulations on the Levels of Selected Markers Associated With Cardiovascular Disease

Completed NA Last updated 23 August 2023
What this trial tests

NA trial testing Complex product in Hypertension in 40 participants. Completed in 28 July 2023.

Timeline
20 February 2023
Primary endpoint
28 July 2023
28 July 2023

Quick facts

Lead sponsorAronPharma Sp. z o. o.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeother
Enrollment40
Start date20 February 2023
Primary completion28 July 2023
Estimated completion28 July 2023
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

AronPharma Sp. z o. o.

Who can join

Adults 18 to 55, any sex, with Hypertension or Hypercholesterolemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to compare in a clinical condition the effect of standardized chokeberry extract in different formulations and a complex preparation containing chokeberry extract and other active ingredients in on the levels of selected markers associated with cardiovascular diseases in people with a predisposition to the development of these diseases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Complex product

Trials testing the same drug.

Other recruiting trials for Hypertension

Currently open trials in the same condition.

Other AronPharma Sp. z o. o. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05988099.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing